Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPEST: Odiparcil for VTE Prevention in Hip Arthroplasty
NCT00041509Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2002
- Primary completion
- May 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of odiparcil in venous thromboembolism (VTE) (3 arms), sponsored by GSK. Primary endpoint: Venous Thromboembolism at 28 days. Started Jan 2002; status: completed.
02
Drugs
odiparcil
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00041509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041509.